---
figid: PMC5372601__ijms-18-00585-g001
figlink: /pmc/articles/PMC5372601/figure/ijms-18-00585-f001/
number: F1
caption: RAS/RAF/MEK aberrant signaling and mechanisms of resistance to inhibition
  in melanoma. Oncogenic BRAFV600E cells become independent from external growth factors
  (GF) (triangle symbol marked with a X) and other stimuli leading to constitutive
  activation of the MAPK pathway. Increased MAPK signalling (four arrows) eventually
  leads to enhanced gene expression including MAP kinase phosphatases (DUSPs) and
  sprouty proteins (SPRYs). Despite elevation of those important inhibitory regulators
  (T lines) of the MAPK pathway, tumour cells adapt and rely on neighbour pathways,
  such as the PI3K pathway, to grow and survive, Furthermore, negative inhibitory
  mechanisms of the MAPK pathway, including inactivation of BRAF via ERK1/2, are now
  lessened (faded T) due to conformational changes in the BRAF. Conferred mechanisms
  of resistance to BRAF inhibitors including up-regulation of PDGFRB, RAS mutations,
  elevation of CRAF, BRAFV600E amplification, alternative splicing of BRAFV600E, elevation
  of COT (MAP3K8), MEK mutation, PTEN loss, PI3K and AKT mutations were highlighted
  in green.
pmcid: PMC5372601
papertitle: Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations.
reftext: Nourah Mohammad Obaid, et al. Int J Mol Sci. 2017 Mar;18(3):585.
pmc_ranked_result_index: '16242'
pathway_score: 0.9590061
filename: ijms-18-00585-g001.jpg
figtitle: RAS/RAF/MEK aberrant signaling and mechanisms of resistance to inhibition
  in melanoma
year: '2017'
organisms: Homo sapiens
ndex: 27be2fd4-dedf-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5372601__ijms-18-00585-g001.html
  '@type': Dataset
  description: RAS/RAF/MEK aberrant signaling and mechanisms of resistance to inhibition
    in melanoma. Oncogenic BRAFV600E cells become independent from external growth
    factors (GF) (triangle symbol marked with a X) and other stimuli leading to constitutive
    activation of the MAPK pathway. Increased MAPK signalling (four arrows) eventually
    leads to enhanced gene expression including MAP kinase phosphatases (DUSPs) and
    sprouty proteins (SPRYs). Despite elevation of those important inhibitory regulators
    (T lines) of the MAPK pathway, tumour cells adapt and rely on neighbour pathways,
    such as the PI3K pathway, to grow and survive, Furthermore, negative inhibitory
    mechanisms of the MAPK pathway, including inactivation of BRAF via ERK1/2, are
    now lessened (faded T) due to conformational changes in the BRAF. Conferred mechanisms
    of resistance to BRAF inhibitors including up-regulation of PDGFRB, RAS mutations,
    elevation of CRAF, BRAFV600E amplification, alternative splicing of BRAFV600E,
    elevation of COT (MAP3K8), MEK mutation, PTEN loss, PI3K and AKT mutations were
    highlighted in green.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3R3
  - PDGFRB
  - PTEN
  - NRAS
  - DUSP1
  - PIK3R5
  - PIK3R4
  - DUSP4
  - PIK3CD
  - HRAS
  - AKT3
  - PIK3CA
  - RAF1
  - FGFR2
  - DUSP2
  - KRAS
  - PIK3CB
  - PIK3R6
  - FGFR1
  - SOS2
  - SOS1
  - MAPK1
  - PIK3CG
  - MAPK3
  - AKT1
  - FGFR3
  - CROT
  - FGFR4
  - DUSP3
  - MTOR
  - FGFRL1
  - DUSP5
  - DUSP6
  - EGFR
  - AKT2
  - MAP2K2
  - MAP2K1
  - PDGFRA
  - GRB2
  - Cancer
  - Lung cancer
  - Noonan syndrome
genes:
- word: P13K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PDGFRB,RTKS
  symbol: PDGFRB
  source: hgnc_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: DUSP
  symbol: DUSP
  source: bioentities_symbol
  hgnc_symbol: DUSP1
  entrez: '1843'
- word: P13K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: P13K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: DUSP
  symbol: DUSP
  source: bioentities_symbol
  hgnc_symbol: DUSP4
  entrez: '1846'
- word: P13K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: P13K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: CRAF
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RTKS(EGFR,FGFR,PDGFR,etc.)
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR2
  entrez: '2263'
- word: DUSP
  symbol: DUSP
  source: bioentities_symbol
  hgnc_symbol: DUSP2
  entrez: '1844'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: P13K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: P13K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: RTKS(EGFR,FGFR,PDGFR,etc.)
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR1
  entrez: '2260'
- word: SOS
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: SOS
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: P13K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: RTKS(EGFR,FGFR,PDGFR,etc.)
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR3
  entrez: '2261'
- word: COT
  symbol: COT
  source: hgnc_alias_symbol
  hgnc_symbol: CROT
  entrez: '54677'
- word: RTKS(EGFR,FGFR,PDGFR,etc.)
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR4
  entrez: '2264'
- word: DUSP
  symbol: DUSP
  source: bioentities_symbol
  hgnc_symbol: DUSP3
  entrez: '1845'
- word: mTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: RTKS(EGFR,FGFR,PDGFR,etc.)
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFRL1
  entrez: '53834'
- word: DUSP
  symbol: DUSP
  source: bioentities_symbol
  hgnc_symbol: DUSP5
  entrez: '1847'
- word: DUSP
  symbol: DUSP
  source: bioentities_symbol
  hgnc_symbol: DUSP6
  entrez: '1848'
- word: (EGFR,
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: RTKS(EGFR,FGFR,PDGFR,etc.)
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: RTKS(EGFR,FGFR,PDGFR,etc.)
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MEK1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: GRB2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC5372601__F1
redirect_from: /figures/PMC5372601__F1
figtype: Figure
---
